Ieq Capital LLC Boosts Holdings in Teleflex Incorporated (NYSE:TFX)

Ieq Capital LLC grew its position in Teleflex Incorporated (NYSE:TFX) by 178.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,890 shares of the medical technology company’s stock after purchasing an additional 8,257 shares during the quarter. Ieq Capital LLC’s holdings in Teleflex were worth $2,294,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of TFX. Creative Planning boosted its position in shares of Teleflex by 7.8% in the 3rd quarter. Creative Planning now owns 5,671 shares of the medical technology company’s stock worth $1,403,000 after purchasing an additional 412 shares in the last quarter. Blue Trust Inc. boosted its holdings in Teleflex by 47.2% in the third quarter. Blue Trust Inc. now owns 312 shares of the medical technology company’s stock worth $77,000 after acquiring an additional 100 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Teleflex by 41.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 24,301 shares of the medical technology company’s stock worth $6,010,000 after acquiring an additional 7,132 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Teleflex by 29,127.3% during the third quarter. International Assets Investment Management LLC now owns 3,215 shares of the medical technology company’s stock worth $795,000 after acquiring an additional 3,204 shares during the last quarter. Finally, E. Ohman J or Asset Management AB increased its holdings in shares of Teleflex by 37.5% during the third quarter. E. Ohman J or Asset Management AB now owns 2,200 shares of the medical technology company’s stock valued at $544,000 after acquiring an additional 600 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on TFX shares. Truist Financial dropped their target price on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Royal Bank of Canada cut their target price on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. StockNews.com raised Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Finally, Mizuho decreased their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $246.00.

Teleflex Stock Up 0.2 %

Shares of TFX opened at $175.43 on Monday. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The firm has a market cap of $8.15 billion, a P/E ratio of 34.88, a PEG ratio of 1.73 and a beta of 1.16. The stock’s 50 day moving average is $176.98 and its two-hundred day moving average is $207.23. Teleflex Incorporated has a 12 month low of $165.62 and a 12 month high of $249.90.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.